Warning! GuruFocus detected
1 Medium warning sign
with MEDP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Medpace Holdings Inc
NAICS : 541714
SIC : 8731
ISIN : US58506Q1094
Compare
Compare
Traded in other countries / regions
MEDP.USA01P.GermanyMEDP.Mexico Index Membership
Russell 1000Russell 3000Russell 2000 IPO Date
2016-08-11Description
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.3 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 0.27 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 6.05 | |||||
| Beneish M-Score | -3.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 29.5 | |||||
| 3-Year EBITDA Growth Rate | 36.6 | |||||
| 3-Year EPS without NRI Growth Rate | 38.6 | |||||
| 3-Year FCF Growth Rate | 42.1 | |||||
| 3-Year Book Growth Rate | 0.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 7.69 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.12 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.95 | |||||
| 9-Day RSI | 43.18 | |||||
| 14-Day RSI | 42.63 | |||||
| 3-1 Month Momentum % | -2.22 | |||||
| 6-1 Month Momentum % | -2.84 | |||||
| 12-1 Month Momentum % | -16.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.93 | |||||
| Quick Ratio | 0.93 | |||||
| Cash Ratio | 0.61 | |||||
| Days Sales Outstanding | 49.66 | |||||
| Days Payable | 7.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 5.2 | |||||
| Shareholder Yield % | 2.42 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 31.12 | |||||
| Operating Margin % | 21.19 | |||||
| Net Margin % | 19.17 | |||||
| FCF Margin % | 27.13 | |||||
| ROE % | 54.63 | |||||
| ROA % | 21.16 | |||||
| ROIC % | 20.97 | |||||
| 3-Year ROIIC % | 38.49 | |||||
| ROC (Joel Greenblatt) % | 173.74 | |||||
| ROCE % | 49.25 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.08 | |||||
| Forward PE Ratio | 24.68 | |||||
| PE Ratio without NRI | 24.08 | |||||
| Shiller PE Ratio | 64.57 | |||||
| Price-to-Owner-Earnings | 17.89 | |||||
| PEG Ratio | 0.77 | |||||
| PS Ratio | 4.6 | |||||
| PB Ratio | 11.28 | |||||
| Price-to-Tangible-Book | 72.41 | |||||
| Price-to-Free-Cash-Flow | 17.01 | |||||
| Price-to-Operating-Cash-Flow | 15.96 | |||||
| EV-to-EBIT | 20 | |||||
| EV-to-Forward-EBIT | 19.79 | |||||
| EV-to-EBITDA | 18.77 | |||||
| EV-to-Forward-EBITDA | 18.54 | |||||
| EV-to-Revenue | 4.24 | |||||
| EV-to-Forward-Revenue | 4.13 | |||||
| EV-to-FCF | 15.62 | |||||
| Price-to-GF-Value | 0.87 | |||||
| Price-to-Projected-FCF | 1.79 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.96 | |||||
| Price-to-Graham-Number | 8.8 | |||||
| Earnings Yield (Greenblatt) % | 5 | |||||
| FCF Yield % | 6.18 | |||||
| Forward Rate of Return (Yacktman) % | 23.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MEDP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Medpace Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,109.054 | ||
| EPS (TTM) ($) | 12.63 | ||
| Beta | 1.32 | ||
| 3-Year Sharpe Ratio | 0.71 | ||
| 3-Year Sortino Ratio | 1.51 | ||
| Volatility % | 19.93 | ||
| 14-Day RSI | 42.63 | ||
| 14-Day ATR ($) | 11.190429 | ||
| 20-Day SMA ($) | 321.279 | ||
| 12-1 Month Momentum % | -16.61 | ||
| 52-Week Range ($) | 289.01 - 459.77 | ||
| Shares Outstanding (Mil) | 30.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medpace Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medpace Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medpace Holdings Inc Frequently Asked Questions
What is Medpace Holdings Inc(MEDP)'s stock price today?
The current price of MEDP is $304.11. The 52 week high of MEDP is $459.77 and 52 week low is $289.01.
When is next earnings date of Medpace Holdings Inc(MEDP)?
The next earnings date of Medpace Holdings Inc(MEDP) is 2025-04-21.
Does Medpace Holdings Inc(MEDP) pay dividends? If so, how much?
Medpace Holdings Inc(MEDP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers